Expanding Horizons Across Europe, Middle East & Africa
The EMEA region encompassing Europe (UK, Nordics, and Strides Pharma International AG), the Middle East, and Africa is a diverse and strategically important cluster for Strides Pharma. Through a mix of owned entities and local partnerships including Trinity Pharma, United Corporate Limited (UCL), and Brands Africa (Branded Generics Business). We have established a strong foundation to serve both mature and emerging healthcare markets with high-quality, accessible medicines.
Our European presence, anchored by operations in the UK, Nordics & Strides Pharma International AG focuses on differentiated generics and value-added offerings tailored to the needs of regional healthcare systems. We combine regulatory expertise with a growing product pipeline to serve retail, hospital, and pharmacy-led distribution networks.
In the Middle East and Africa, we operate through a combination of marketing-led models and trusted partnerships, enabling us to reach a broad base of patients with proven therapies. Our portfolio includes a mix of branded generics, prescription medicines, and over the counter (OTC) products, catering to local therapeutic priorities across infectious diseases, pain management, cardiology, and wellness.
With a unique blend of market-specific strategies, regulatory agility, and a strong partner ecosystem, Strides’ EMEA operations are poised to scale further, expanding our impact and reinforcing our commitment to affordable healthcare across continents.
Strides Supporting UK Healthcare with Purpose
Founded in 1993 and headquartered in Watford, England, Strides Pharma UK Limited operates under three core values of reliability, quality and value to serve the UK pharmaceutical market. As the UK arm of Strides Pharma Science, the company focuses on licensing, marketing, and supplying generic and OTC medicines, backed by a robust global supply network. With its own API production and four overseas manufacturing sites approved by the MHRA, Strides UK maintains consistent stock levels (typically held at least six months ahead) to ensure uninterrupted availability and support for its partners.
Strides UK is committed to upholding the highest manufacturing and distribution standards. The company’s operations in Watford, including its Metro Centre facility, are fully MHRA-approved with GMP certification. Driven by a mission to develop a differentiated portfolio of generics, branded generics, and OTC products, Strides UK combines local insight with the global strengths of its parent organization. This alignment allows for agile responses to the evolving needs of UK patients and healthcare professionals, reinforcing trust and presence in one of Europe’s key regulated markets.
Strides Nordics Delivering Quality Generics Across Scandinavia
Strides Nordic, a subsidiary of Strides Pharma Science Limited, is headquartered in Denmark and plays a strategic role in our footprint across the Scandinavian region. Focused on the distribution of high-quality generic formulations, Strides Nordics brings global manufacturing strength to one of Europe’s most quality-conscious and regulated healthcare markets.
Operating within Denmark’s stringent regulatory environment and aligned with international pharmaceutical standards, Strides Nordics ensures full compliance, traceability, and ethical governance across its distribution practices reinforcing trust in every product we deliver. This reflects not only local governance standards but also Strides’ global commitment to quality, patient safety, and regulatory excellence.
Backed by the wider capabilities of Strides Pharma Science including advanced R&D, vertically integrated manufacturing, and a diverse dosage portfolio, Strides Nordics is well-positioned to support the evolving needs of healthcare systems across Denmark and the greater Nordic region.
Strides Pharma International AG Expanding Reach Across Continental Europe
Headquartered in Zug, Switzerland, Strides Pharma International AG (formerly Fairmed Healthcare AG) is a key pillar of Strides Pharma’s European growth strategy. Founded in 2012 and fully acquired by Strides Pharma Science Limited, the company is focused on making high-quality, cost-effective medicines accessible across Germany, Austria, and Switzerland, some of Europe’s most advanced and regulated healthcare markets.
With a portfolio spanning prescription generics, OTC products, dermo cosmetics, and dietary supplements, the business leverages Strides’ global R&D and manufacturing scale to deliver impactful therapies with precision and speed. The integration into Strides Pharma has amplified its capabilities, combining robust product development with deep market access, especially in the DACH region.
Through continuous regulatory filings, marketing authorisations, and investments in patient-centric solutions, Strides Pharma International AG plays a pivotal role in strengthening Strides’ presence in continental Europe while advancing affordable healthcare in highly regulated, reference-driven pharmaceutical markets.
Strides Pharma Middle East
Strides operates in the Middle East through a partnership-led model, supported by supply from our global manufacturing network. We are working with local contract manufacturing partners to ensure timely access and compliance with regional requirements.
Our business follows a license, supply, and distribution structure, with product registrations held under Strides’ marketing authorisations. Regulatory standards in the region align with global norms, with additional stability data required due to the region’s climatic conditions.
The current portfolio focuses on prescription medicines, catering to priority healthcare needs across key markets in the region.
Brands Africa Elevating Access with Trusted, Localised Generics
Africa has long been an integral part of Strides Pharma’s global story. It was the first region we entered in the early 1990s, and today, it remains one of our most dynamic growth markets. Our branded generics business in Africa, Brands Africa, embodies our enduring philosophy of "In Africa for Africa," where we combine global pharmaceutical standards with deep local insight to deliver affordable, relevant, and high-quality medicines across the continent.
To meet the unique needs of African healthcare systems, we’ve built a model that centres on localisation, accessibility, and trust. Our branded generics are manufactured through a regional supply chain, anchored by our WHO-prequalified manufacturing facility in Kenya (Universal Corporations Limited) and a dedicated emerging markets facility in India. This regional footprint not only ensures agility in supply but also aligns with pricing and regulatory realities in the continent, helping us bring therapeutic solutions closer to those who need them most.
Brands Africa has a commercial presence in over 40 African countries and continues to strengthen its reach through a robust field force, deep engagement with local healthcare professionals, and a portfolio that reflects local disease priorities. With established brands like Renerve, Combiart, Duotab, Vitafer, and Unibrol, we’re already making a meaningful impact in the treatment of neuropathy, anaemia, malaria, and other widely prevalent conditions. Our brand equity among doctors and pharmacies has grown steadily, thanks to our focus on clinical relevance, therapeutic efficacy, and consistent availability.
As the African pharmaceutical market evolves, driven by rising urbanisation, expanding healthcare access, and growing demand for chronic care, we are expanding our pipeline to include differentiated offerings in Women’s Health, CNS, Cardiovascular, Diabetes, Dermatology, and Probiotics. With multiple registrations in progress, our aim is to build leadership in chronic therapies while continuing to support acute care categories with proven, affordable options.
Brands Africa is not just a commercial operation but a commitment to improving the quality of life for millions across the continent. Through our integrated, patient-first approach, we’re proud to play a role in Africa’s healthcare journey, delivering medicines that are recognised, remembered, and trusted.
Universal Corporate Limited (UCL) Local Manufacturing for Global Impact
As part of its commitment to expanding access to high-quality medicines across Africa and other emerging markets, Strides Pharma Science Limited has partnered with Universal Corporation Limited (UCL), a WHO-prequalified pharmaceutical manufacturer based in Kikuyu, Kenya. This partnership is a cornerstone of Strides’ “In Africa, for Africa” strategy, enabling regionally anchored manufacturing and distribution that directly supports over 30 countries across Africa, the Middle East, and key donor-driven markets.
UCL serves as an extended manufacturing arm for Strides under global donor-funded contracts, including critical formulations like TLD (Tenofovir/Lamivudine/Dolutegravir) and Artemether/Lumefantrine, which are vital to HIV/AIDS and malaria treatment programs. With GMP certification from the Pharmacy and Poisons Board of Kenya and approvals from multiple international regulators, UCL’s facility meets the highest global quality benchmarks. The site manufactures over 100 formulations across multiple dosage forms, ensuring supply continuity to agencies like UNICEF, USAID, the Global Fund, WHO, and Iplus.
Strides’ collaboration with UCL enhances its ability to meet regional health needs while fostering pharmaceutical self-sufficiency in Sub-Saharan Africa. UCL’s WHO-prequalified portfolio includes products for malaria prevention (SP, SPAQ) and child health, placing it among a select group of manufacturers globally trusted for critical disease interventions.
Through this strategic alliance, Strides not only scales its branded and donor-backed offerings but also helps drive local impact, supporting job creation, regulatory capability building, and stronger public health outcomes in one of the world’s fastest-growing healthcare markets.
Trinity Pharma Expanding Access Through Strategic Partnership
To strengthen its presence in South Africa and the broader Southern African region, Strides Pharma partnered with Trinity Pharma, a leading South Africa-based pharmaceutical company. This strategic collaboration allows Strides to bring its high-quality, affordable generic medicines to key markets including South Africa, Namibia, Botswana, and Lesotho, across both the private and public healthcare sectors. With a broad therapeutic footprint spanning all major categories except oncology, Trinity plays a pivotal role in bridging global innovation with regional healthcare needs.
With deep-rooted regulatory expertise and established market access, Trinity plays a pivotal role in navigating one of the world’s most stringently regulated pharmaceutical landscapes. Together, Strides and Trinity offer a robust portfolio spanning multiple therapeutic areas excluding oncology while ensuring compliance with standards comparable to the UK MHRA and Australian TGA. This partnership is a key enabler in Strides’ commitment to improving access to essential medicines across Southern Africa.
